A point-of-care device for diagnosis and management of pulmonary diseases

用于诊断和管理肺部疾病的床旁设备

基本信息

批准号：
1804416
负责人：
Stefan Bossmann
金额：
$ 32.5万
依托单位：
Kansas State University
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2018
资助国家：
美国
起止时间：
2018-05-01 至 2021-04-30
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=1804416&HistoricalAwards=false
关键词：
point care device diagnosis management

项目摘要

Lung cancer is the most common cause of cancer-related death. Symptoms, such as fever or fatigue, are unspecific while other indicators are typical of many other diseases. Development of a reliable technique that detects lung cancer at the earliest possible stage, is critical for successful outcomes. Several competing techniques demonstrated their ability to diagnose intermediate and late stage lung cancer, but failed to detect early stage cancer which significantly decreases their utility. This project will synthesize a set of novel optical biosensors and indicators that have been implicated in early stage lung cancer. The development of this novel non-invasive, cost effective, and reliable screening tool would be transformative for the whole field of lung cancer prevention.The team will achieve technical proof-of-principle by focusing on a set of biomarkers (matrix metalloproteinases and cathepsins) that have been shown to be successful in detecting stage 1 non-small-cell lung cancer (NSCLC), the most common form of lung cancer. An integrated microfluidic device will be developed to handle a new class of nano-biosensors designed to detect a large number of enzymes. The panel of biomarkers that will be detected by the proposed device will be optimized based on samples collected from animal models first, and human patients later.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteriaThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

肺癌是癌症相关死亡的最常见原因。症状（例如发烧或疲劳）是不明显的，而其他指标是许多其他疾病的典型特异性。开发可靠的技术，该技术最早可能在可能的阶段检测到肺癌，这对于成功的结果至关重要。几种竞争技术证明了他们诊断中间肺癌和晚期肺癌的能力，但未能检测到早期癌症，从而大大降低了效用。该项目将综合一组与早期肺癌有关的新型光学生物传感器和指标。这种新颖的非侵入性，具有成本效益和可靠的筛查工具的开发对于整个肺癌预防领域都将具有变革性。该团队将通过关注一组生物标志物（基质金属蛋白酶和calter蛋白酶和calter蛋白）来实现技术证明，这些生物标志物已在检测1阶段的1阶段非级别癌症（ns cance）（ns cance）（NS cance）中，这些形式均可在ns cance（NS Cance）中获得成功。将开发一种集成的微流体设备来处理一类新的纳米生物传感器，旨在检测大量酶。该拟议设备将检测到的生物标志物将根据动物模型收集的样本进行优化，以后人类患者。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子和更广泛影响的审查标准通过Infactiral Infortional Internitory of Nectirory of Forner的构建范围来评估的，并通过评估进行了评估，这是值得评估的。影响审查标准。

项目成果

期刊论文数量（4）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Magnetic Nanomaterials for Magnetically-Aided Drug Delivery and Hyperthermia

DOI：
10.3390/app9142927
发表时间：
2019-07-02
期刊：
APPLIED SCIENCES-BASEL
影响因子：
2.7
作者：
Kalubowilage, Madumali;Janik, Katharine;Bossmann, Stefan H.
通讯作者：
Bossmann, Stefan H.

Nano-Inspired Technologies for Peptide Delivery

DOI：
10.2174/1389203720666191202112429
发表时间：
2020-01-01
期刊：
CURRENT PROTEIN & PEPTIDE SCIENCE
影响因子：
2.8
作者：
Covarrubias-Zambrano，Obdulia;Yu，Jing;Bossmann，Stefan H.
通讯作者：
Bossmann，Stefan H.

Early detection of non-small cell lung cancer in liquid biopsies by ultrasensitive protease activity analysis

通过超灵敏蛋白酶活性分析在液体活检中早期检测非小细胞肺癌

DOI：
10.20517/2394-4722.2020.45
发表时间：
2020
期刊：
Journal of Cancer Metastasis and Treatment
影响因子：
0
作者：
Udukala, Dinusha N.;Wendel, Sebastian O.;Wang, Hongwang;Yapa, Asanka S.;Covarrubias-Zambrano, Obdulia;Janik, Katharine;Gadbury, Gary;Troyer, Deryl L.;Bossmann, Stefan H.
通讯作者：
Bossmann, Stefan H.